Physician profile
George Ghata
NPI 1487002556
$7,006.97
in general payments reported to CMS, 2019-2025
13 companies · $2,848 in 2025
The $2,848 reported for 2025 was more than what 96% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $577 · 2023: $1,991 · 2024: $1,591 · 2025: $2,848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,200 · Food and Beverage: $1,632 · Travel and Lodging: $598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,200.00 |
| Food and Beverage | $1,631.83 |
| Travel and Lodging | $598.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Trice Medical, INC. | $5,737.98 | 2022-2025 | |
| Nalu Medical, INC. | $485.17 | 2023-2024 | Nalu Neurostimulation System |
| Pacira Pharmaceuticals Incorporated | $254.48 | 2023-2025 | Iovera, Zilretta, Exparel |
| Inari Medical, INC. | $161.83 | 2022 | |
| Zimmer Biomet Holdings, INC. | $149.84 | 2023 | Gps III Platelet Concentration System |
| Pylant Medical | $61.10 | 2024 | |
| Horizon Therapeutics Plc | $47.92 | 2022 | |
| Akebia Therapeutics INC | $24.12 | 2025 | Vafseo |
| Alexion Pharmaceuticals, INC. | $22.11 | 2025 | Strensiq |
| Takeda Pharmaceuticals U.S.A., INC. | $18.47 | 2023 | Trintellix |
| Amgen INC. | $14.85 | 2023 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $14.78 | 2023 | Verquvo, Belsomra, Steglatro |
| Depuy Synthes Sales INC. | $14.32 | 2025 | Monovisc |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Ghata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.